

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT2740794

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
ALDER BIOPHARMACEUTICALS, INC.	02/24/2014
RECEIVING PARTY DATA	
Name:	ALDERBIO HOLDINGS LLC
Street Address:	101 CONVENTION CENTER DRIVE
Internal Address:	SUITE 850
City:	LAS VEGAS
State/Country:	NEVADA
Postal Code:	89109
PROPERTY NUMBERS Total: 27	
Property Type	Number
Application Number:	13070583
Application Number:	61842745
Application Number:	13803768
Application Number:	61905620
Application Number:	61791471
Application Number:	61792935
Application Number:	61782868
Application Number:	61791755
Application Number:	13833824
Application Number:	13833338
Application Number:	13046860
Application Number:	61887666
Application Number:	61756526
Application Number:	60850258

Application Number:	11870180
Application Number:	13542851
Application Number:	61117839
Application Number:	60513876
Application Number:	10577074
Application Number:	11429053
Application Number:	13598885
Application Number:	60801412
Application Number:	11802235
Application Number:	13204915
Application Number:	13861518
Application Number:	13834458
Application Number:	13834889

CORRESPONDENCE DATA

Fax Number: (703)684-8075
 Phone: 703 684 8007
 Email: david.mckim@leclairryan.com
Correspondence will be sent via US Mail when the email attempt is unsuccessful.
 Correspondent Name: LECLAIRRYAN, A PROFESSIONAL CORPORATION
 Address Line 1: 2318 MILL ROAD
 Address Line 2: SUITE 1100
 Address Line 4: ALEXANDRIA, VIRGINIA 22314

ATTORNEY DOCKET NUMBER:	43257.0001
NAME OF SUBMITTER:	DAVID P. MCKIM
Signature:	/David P. McKim/
Date:	02/25/2014

Total Attachments: 5

source=ALDERBIOPHARM_ALDERBIOHOLDINGS#page1.tif
 source=ALDERBIOPHARM_ALDERBIOHOLDINGS#page2.tif
 source=ALDERBIOPHARM_ALDERBIOHOLDINGS#page3.tif
 source=ALDERBIOPHARM_ALDERBIOHOLDINGS#page4.tif
 source=ALDERBIOPHARM_ALDERBIOHOLDINGS#page5.tif

ASSIGNMENT

WHEREAS, ALDER BIOPHARMACEUTICALS, INC., a corporation organized under the laws of the State of Delaware, having a place of business located at 11804 North Creek Parkway South, Bothell, Washington, 98011, ("Assignor") is the owner of the entire right, title and interest in and to the following patent applications:

Application No.	TITLE OF INVENTION	Filing date
13/070,583	<i>METHODS OF SYNTHESIZING HETEROMULTIMERIC POLYPEPTIDES IN YEAST USING A HAPLOID MATING STRATEGY</i>	March 24, 2011
61/842,745	<i>REGULATION OF GLUCOSE METABLISM USING ANTI-CGRP ANTIBODIES</i>	July 3, 2013
13/803,768	<i>THERAPEUTIC USE OF ANTIBODIES TO HGF</i>	March 14, 2013
61/905,620	<i>COMPOSITIONS ABLE TO CROSS THE BLOOD BRAIN BARRIER AND METHODS OF USING SAME</i>	November 18, 2013
61/791,471	<i>TEMPERATURE SHIFT FOR HIGH YIELD EXPRESSION OF POLYPEPTIDES IN YEAST AND OTHER TRANSFORMED CELLS</i>	March 15, 2013
61/792,935	<i>ANTIBODY PURIFICATION AND PURITY MONITORING</i>	March 15, 2013
61/782,868	<i>ANTIBODIES TO HGF AND COMPOSITIONS CONTAINING</i>	March 14, 2013
61/791,755	<i>PROTOCOL FOR IDENTIFYING AND ISOLATING ANTIGEN-SPECIFIC B CELLS AND PRODUCING ANTIBODIES TO DESIRED ANTIGENS</i>	March 15, 2013
13/833,824	<i>METHODS OF PREVENTING OR TREATING PAIN USING ANTI-NGF ANTIBODIES THAT SELECTIVELY INHIBIT THE ASSOCIATION OF NGF WITH TRKA, WITHOUT AFFECTING THE ASSOCIATION OF NGF WITH P75</i>	March 15, 2013
13/833,338	<i>ANTI-NGF COMPOSITIONS AND USE THEREOF</i>	March 15, 2013

13/046,860	<i>ANTAGONISTS OF IL-6 TO PREVENT OR TREAT CACHEXIA, WEAKNESS, FATIGUE, AND/OR FEVER</i>	March 14, 2011
61/887,666	<i>ANTI-IL-6 ANTIBODIES FOR THE TREATMENT OF PSORIATIC ARTHRITIS</i>	October 7, 2013
61/756,526	<i>ANTI-IL-6 ANTIBODIES FOR THE TREATMENT OF CROHN'S DISEASE</i>	January 25, 2013
60/850,258	<i>NOVEL P. PASTORIS PASTORIS PROMOTERS, AND THE USE THEREOF TO DIRECT EXPRESSION OF PROTEINS IN YEAST, PREFERABLY USING A HAPLOID MATING STRATEGY</i>	October 10, 2006
11/870,180	<i>NOVEL P. PASTORIS ADH PROMOTER AND USE THEREOF TO DIRECT EXPRESSION OF PROTEINS</i>	October 10, 2007
13/542,851	<i>NOVEL P. PASTORIS PASTORIS PROMOTERS, AND THE USE THEREOF TO DIRECT EXPRESSION OF PROTEINS IN YEAST, PREFERABLY USING A HAPLOID MATING STRATEGY</i>	July 6, 2012
PCT/US07/021649	<i>NOVEL P. PASTORIS PASTORIS PROMOTERS, AND THE USE THEREOF TO DIRECT EXPRESSION OF PROTEINS IN YEAST, PREFERABLY USING A HAPLOID MATING STRATEGY</i>	October 10, 2007
61/117,839	<i>ANTAGONISTS OF IL-6 TO PREVENT OR TREAT CACHEXIA, WEAKNESS, FATIGUE, AND/OR FEVER</i>	November 25, 2008
PCT/US09/06274	<i>ANTIBODIES TO IL-6 AND USE THEREOF</i>	November 24, 2009
PCT/US09/06257	<i>ANTAGONISTS OF IL-6 TO RAISE ALBUMIN AND/OR LOWER CRP</i>	November 24, 2009
PCT/US09/06266	<i>ANTAGONISTS OF IL-6 TO PREVENT OR TREAT THROMBOSIS</i>	November 24, 2009
PCT/US09/06273	<i>ANTAGONISTS OF IL-6 TO PREVENT OR TREAT CACHEXIA, WEAKNESS, FATIGUE, AND/OR FEVER</i>	November 24, 2009

60/513,876	<i>METHODS OF SYNTHESIZING HETEROMULTIMERIC POLYPEPTIDES IN YEAST USING A HAPLOID MATING STRATEGY</i>	October 22, 2003
10/577,074	<i>METHODS OF SYNTHESIZING HETEROMULTIMERIC POLYPEPTIDES IN YEAST USING A HAPLOID MATING STRATEGY</i>	May 7, 2007
PCT/US04/035302	<i>METHODS OF SYNTHESIZING HETEROMULTIMERIC POLYPEPTIDES IN YEAST USING A HAPLOID MATING STRATEGY</i>	October 22, 2004
11/429,053	<i>METHODS OF SYNTHESIZING HETEROMULTIMERIC POLYPEPTIDES IN YEAST USING A HAPLOID MATING STRATEGY</i>	May 8, 2006
13/598,885	<i>METHODS OF SYNTHESIZING HETEROMULTIMERIC POLYPEPTIDES IN YEAST USING A HAPLOID MATING STRATEGY</i>	August 30, 2012
60/801,412	<i>METHODS OF ISOLATING ANTIGEN-SPECIFIC CELLS AND PRODUCING ANTIBODIES THEREFROM</i>	May 19, 2006
11/802,235	<i>CULTURE METHOD FOR OBTAINING A CLONAL POPULATION OF ANTIGEN-SPECIFIC B CELLS</i>	May 21, 2007
PCT/US08064421	<i>NOVEL RABBIT ANTIBODY HUMANIZATION METHODS AND HUMANIZED RABBIT ANTIBODIES</i>	May 21, 2008
13/204,915	<i>CULTURE METHOD FOR OBTAINING A CLONAL POPULATION OF ANTIGEN-SPECIFIC B CELLS</i>	August 8, 2011
13/861,518	<i>CULTURE METHOD FOR OBTAINING A CLONAL POPULATION OF ANTIGEN-SPECIFIC B CELLS</i>	April 12, 2013
13/834,458	<i>METHODS OF PREVENTING INFLAMMATION AND TREATING PAIN USING ANTI-NGF COMPOSITIONS</i>	March 15, 2013
13/834,889	<i>METHODS OF PREVENTING OR TREATING PAIN USING ANTI-NGF ANTIBODIES</i>	March 15, 2013

AND, WHEREAS, AlderBio Holdings LLC, a Nevada limited liability company having its principal place of business at 101 Convention Center Drive, Suite 850, Las Vegas, Nevada, 89109, (hereinafter "Assignee"), is desirous of acquiring certain rights to the improvements and under the application;

NOW, THEREFORE, in exchange for good and valuable consideration, receipt of which is hereby acknowledged, we do hereby sell, assign and transfer unto said ASSIGNEE, its successors, assigns and legal representatives, my entire right, title and interest in and throughout the United States of America (including its territories and dependencies) and all countries foreign thereto in and to said improvements, said United States application, any other United States applications, including provisional, non-provisional, divisional, renewal, substitute, continuation, continuation-in-part, reexamination and reissue applications, based in whole or in part on said United States application or in whole or in part on said improvements, any foreign applications, including international and regional applications, based in whole or in part on any of the aforesaid United States applications or in whole or in part on said improvements, and in and to any and all letters patent, including extensions thereof, of any country which have been or may be granted on any of the aforesaid applications or on said improvements or any parts thereof;

AND ASSIGNOR, its successors, assigns and legal representatives, hereby authorizes and requests its agents, LeClairRyan, A Professional Corporation, whose address is 2318 Mill Road, Suite 1100, Alexandria, VA, 22314, to insert hereon any identification necessary or desirable for recordation of this document, including the filing date and application number of said application when known.

AND ASSIGNOR, its successors, assigns and legal representatives, hereby agrees to execute without further consideration any further documents and instruments which may be necessary, lawful and proper in the prosecution of said above-referenced application or in the preparation or prosecution of any continuing, substitute, divisional, renewal, reexamination or reissue application or in any amendments, extensions, post-grant review, inter partes review or derivation proceedings, supplemental examination or interference proceedings, or other applications for patents of any region or country, that may be necessary to secure to ASSIGNEE its interest and title in and to said improvements or any parts thereof, and in and to said several patents or any of them;

AND ASSIGNOR hereby covenants and agrees with said ASSIGNEE, its successors and assigns, that ASSIGNOR has granted no right or license to make, use, sell or offer to sell said improvements, to anyone except said ASSIGNEE, that prior to the execution of this deed, ASSIGNOR's right, title and interest in said improvements had not been otherwise encumbered, and that ASSIGNOR has not and will not execute any instrument in conflict therewith;

AND ASSIGNOR does hereby authorize and request the United States Commissioner for Patents to issue any and all letters patent which may be granted upon said United States applications, or upon said improvements or any parts thereof when granted, to said ASSIGNEE.

IN WITNESS WHEREOF, I have hereunto set my hand and seal.

Signature of Officer: _____

Officer's Name: _____

Officer's Title: _____

Company Name: _____

Date of Execution: _____

County of King)

State of Washington)

ss:

On this 24 day of February, 2014, before me a Notary Public in and for the County and State aforesaid, personally appeared Randall C. Schatzman to me known and known to me to be the person of that name, who signed and sealed the foregoing instrument, and acknowledged the same to be of his free act and deed.

(SEAL)



Marilyn N. Singer
Notary Public

My Commission Expires

January 22 2017